Focused On-demand Library for Histidine--tRNA ligase, cytoplasmic

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P12081

UPID:

HARS1_HUMAN

Alternative names:

Histidyl-tRNA synthetase

Alternative UPACC:

P12081; B4DHQ1; B4DY73; D6REN6; J3KNE5

Background:

Histidine--tRNA ligase, cytoplasmic, also known as Histidyl-tRNA synthetase, plays a crucial role in protein synthesis by catalyzing the ATP-dependent ligation of histidine to its cognate tRNA. This process is vital for the accurate translation of mRNA into protein. Additionally, this enzyme has been implicated in axon guidance, highlighting its importance in neural development.

Therapeutic significance:

Histidine--tRNA ligase, cytoplasmic, is linked to Usher syndrome 3B, characterized by progressive vision and hearing loss, and Charcot-Marie-Tooth disease, axonal, 2W, a peripheral neuropathy. Understanding the enzyme's role in these diseases could lead to novel therapeutic strategies targeting its function or pathway.